펩티드 치료제 시장 : 용도별, 투여 경로별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global peptide therapeutics market was valued at $33,257.72 million in 2021, and is estimated to reach $64,336.12 million by 2031, growing at a CAGR of 6.8% from 2022 to 2031. A peptide is a small, chemically bound chain of amino acids, usually between two and fifty amino acids (called peptide bonds). Peptides are smaller than proteins, consisting of about 2 to 50 amino acids. Peptides employed in the therapy of diseases are known as peptide therapies. Peptide treatments replicate such roles that naturally occurring peptides can perform as hormones, growth factors, ion channel ligands, and anti-effectiveness. Given that peptides can be metabolized by the body, peptide therapeutics are thought to be generally safe and well-tolerated.The major factors that drive the growth of the peptide therapeutics market are rise in incidence of chronic diseases such as diabetes, cancer, significant development of peptide therapeutics and growth in R & D for peptide therapeutics, are the factors attributed to the growth of the peptide therapeutics market. In addition, surge in the R & D by the key players is a key trend of the market, which is expected to fuel the growth in the forecast period.

Rise in prevalence of the chronic diseases drives peptide therapeutics market. For an instance, according to the NCBI, National Center for Biotechnology Information, gastrointestinal diseases affect an estimated 60 to 70 million people annually in America and having colorectal cancer as the 2nd leading cancer diagnosed among American men and women. Thus, globally, there has been an increase in prevalence of chronic diseases. which further highlights the need for the peptide therapeutics causing the market growth.

However, poor bioavailability of peptides and high cost associated with drug development are expected to hinder the growth of the market. Conversely, growth opportunities in emerging market to suffice the consumer demands is expected to provide a great opportunity for the investors to invest in the market.

The global peptide therapeutics market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is categorized into metabolic, oncology, gastrointestinal, neurological, cardiovascular and others. By route of administration, it is divided into oral and parenteral. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Hospital pharmacies segment is further bifurcated as private and public. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc, Amgen Inc., Bausch Health Companies Inc, Eli Lilly and company, Ever Neuro Pharma GmbH, GalaxoSmithKline plc, Novo Nordisk, Pfizer Inc, Sanofi-GSK and Takeda Pharmaceutical Company Limited.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peptide therapeutics market analysis from 2021 to 2031 to identify the prevailing peptide therapeutics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the peptide therapeutics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global peptide therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

• Metabolic
• Oncology
• Gastrointestinal
• Neurological
• Cardiovascular
• Others

By Route of administration

• Oral
• Parenteral

By Distribution Channel

• Hospital pharmacies
  • Hospital type
  • Private
  • Public
• Drug store and retail pharmacies
• Online pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Eli Lilly and Company
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Novo Nordisk A/S
  • Sanofi SA
  • Ever Neuro Pharma GmbH
  • Baush Health
  • GlaxoSmithKline plc
  • Abbvie ( Allergan)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: PEPTIDE THERAPEUTICS MARKET, BY APPLICATION

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Metabolic
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Oncology
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Gastrointestinal
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country
• 4.5 Neurological
  • 4.5.1 Key market trends, growth factors and opportunities
  • 4.5.2 Market size and forecast, by region
  • 4.5.3 Market analysis by country
• 4.6 Cardiovascular
  • 4.6.1 Key market trends, growth factors and opportunities
  • 4.6.2 Market size and forecast, by region
  • 4.6.3 Market analysis by country
• 4.7 Others
  • 4.7.1 Key market trends, growth factors and opportunities
  • 4.7.2 Market size and forecast, by region
  • 4.7.3 Market analysis by country

CHAPTER 5: PEPTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Oral
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Parenteral
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country

CHAPTER 6: PEPTIDE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospital pharmacies
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
  • 6.2.4 Hospital pharmacies Peptide Therapeutics Market by Hospital type
    • 6.2.4.1 Private Market size and forecast, by region
    • 6.2.4.2 Public Market size and forecast, by region
• 6.3 Drug store and retail pharmacies
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Online pharmacies
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: PEPTIDE THERAPEUTICS MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Application
  • 7.2.3 North America Market size and forecast, by Route of administration
  • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.4.1 North America Hospital pharmacies Peptide Therapeutics Market by Hospital type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Application
    • 7.2.5.1.2 Market size and forecast, by Route of administration
    • 7.2.5.1.3 Market size and forecast, by Distribution Channel
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Application
    • 7.2.5.2.2 Market size and forecast, by Route of administration
    • 7.2.5.2.3 Market size and forecast, by Distribution Channel
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Application
    • 7.2.5.3.2 Market size and forecast, by Route of administration
    • 7.2.5.3.3 Market size and forecast, by Distribution Channel
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Application
  • 7.3.3 Europe Market size and forecast, by Route of administration
  • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.4.1 Europe Hospital pharmacies Peptide Therapeutics Market by Hospital type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Application
    • 7.3.5.1.2 Market size and forecast, by Route of administration
    • 7.3.5.1.3 Market size and forecast, by Distribution Channel
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Application
    • 7.3.5.2.2 Market size and forecast, by Route of administration
    • 7.3.5.2.3 Market size and forecast, by Distribution Channel
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Application
    • 7.3.5.3.2 Market size and forecast, by Route of administration
    • 7.3.5.3.3 Market size and forecast, by Distribution Channel
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Application
    • 7.3.5.4.2 Market size and forecast, by Route of administration
    • 7.3.5.4.3 Market size and forecast, by Distribution Channel
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Application
    • 7.3.5.5.2 Market size and forecast, by Route of administration
    • 7.3.5.5.3 Market size and forecast, by Distribution Channel
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Application
    • 7.3.5.6.2 Market size and forecast, by Route of administration
    • 7.3.5.6.3 Market size and forecast, by Distribution Channel
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Application
  • 7.4.3 Asia-Pacific Market size and forecast, by Route of administration
  • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.4.1 Asia-Pacific Hospital pharmacies Peptide Therapeutics Market by Hospital type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Application
    • 7.4.5.1.2 Market size and forecast, by Route of administration
    • 7.4.5.1.3 Market size and forecast, by Distribution Channel
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Application
    • 7.4.5.2.2 Market size and forecast, by Route of administration
    • 7.4.5.2.3 Market size and forecast, by Distribution Channel
    • 7.4.5.3 India
    • 7.4.5.3.1 Market size and forecast, by Application
    • 7.4.5.3.2 Market size and forecast, by Route of administration
    • 7.4.5.3.3 Market size and forecast, by Distribution Channel
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Market size and forecast, by Application
    • 7.4.5.4.2 Market size and forecast, by Route of administration
    • 7.4.5.4.3 Market size and forecast, by Distribution Channel
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Application
    • 7.4.5.5.2 Market size and forecast, by Route of administration
    • 7.4.5.5.3 Market size and forecast, by Distribution Channel
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Application
    • 7.4.5.6.2 Market size and forecast, by Route of administration
    • 7.4.5.6.3 Market size and forecast, by Distribution Channel
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Application
  • 7.5.3 LAMEA Market size and forecast, by Route of administration
  • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.4.1 LAMEA Hospital pharmacies Peptide Therapeutics Market by Hospital type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Application
    • 7.5.5.1.2 Market size and forecast, by Route of administration
    • 7.5.5.1.3 Market size and forecast, by Distribution Channel
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Application
    • 7.5.5.2.2 Market size and forecast, by Route of administration
    • 7.5.5.2.3 Market size and forecast, by Distribution Channel
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Application
    • 7.5.5.3.2 Market size and forecast, by Route of administration
    • 7.5.5.3.3 Market size and forecast, by Distribution Channel
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Application
    • 7.5.5.4.2 Market size and forecast, by Route of administration
    • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Eli Lilly and Company
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Amgen Inc.
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Pfizer Inc.
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Takeda Pharmaceutical Company Limited
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Novo Nordisk A/S
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Sanofi SA
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Ever Neuro Pharma GmbH
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Baush Health
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 GlaxoSmithKline plc
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Abbvie ( Allergan)
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments